Pharmacokinetics and tolerability of a new sustained-release formulation of risperidone (RBP-7000) in patients with clinically-stable schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2014
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 22 Mar 2013 New trial record
- 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.